NCT06455306

Brief Summary

This study aimed to evaluate the effectiveness of air polishing systems compared to the exclusive use of oral hygiene instruction in the treatment of peri-implant mucositis

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
24

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Mar 2024

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 18, 2024

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

May 18, 2024

Completed
25 days until next milestone

First Posted

Study publicly available on registry

June 12, 2024

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2025

Completed
Last Updated

June 12, 2024

Status Verified

June 1, 2024

Enrollment Period

1.7 years

First QC Date

May 18, 2024

Last Update Submit

June 6, 2024

Conditions

Keywords

peri-implant mucositiserythritol powder air-polishingnon-surgical treatment

Outcome Measures

Primary Outcomes (1)

  • Changes in Bleeding on Probing compared to baseline

    Bleeding on Probing (BoP) will be evaluated according to the modified bleeding index (0-no BoP; 1- punctiform drop of bleed; 2- confluent red continuous line formed through the sulcus; 3-heavy/profuse), for each site

    Baseline, 3 months and 6 months

Secondary Outcomes (8)

  • Probing Pocket Depth

    Baseline, 3 months and 6 months

  • Plaque index (PI)

    Baseline, 3 months and 6 months

  • Gingival Recession

    Baseline, 3 months and 6 months

  • Radiographic bone level

    Baseline, 3 months and 6 months

  • Biochemical outcomes

    Baseline, 3 months and 6 months

  • +3 more secondary outcomes

Study Arms (3)

Test Group Erythritol Monthly Applications

EXPERIMENTAL

Patients will receive monthly applications (months 0, 1, and 2) of treatment with an air-polishing device with erythritol, along with oral hygiene instructions

Procedure: Air-polishing with erythritol at different time points

Control group

NO INTERVENTION

Patients will receive only oral hygiene instructions

Test Group Erythritol Single Application

EXPERIMENTAL

Patients will receive a single application of treatment with an air-polishing device with erythritol, in addition to oral hygiene instructions

Procedure: Single Air-polishing with erythritol

Interventions

The air-polishing device will be inserted into each site of the peri-implant pocket at an angle ranging from 60 to 90 degrees, and each surface will be debrided for 5 seconds using erythritol powder (AIRFLOW Powder PERIO; EMS). In this group this procedure will be done ate baseline, 1 month and 2 months

Test Group Erythritol Monthly Applications

The air-polishing device will be inserted into each site of the peri-implant pocket at an angle ranging from 60 to 90 degrees, and each surface will be debrided for 5 seconds using erythritol powder (AIRFLOW Powder PERIO; EMS). In this group this procedure will be done ate baseline only.

Test Group Erythritol Single Application

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adults with at least one implant in function for a minimum of one year affected by peri-implant mucositis.

You may not qualify if:

  • Pregnant or lactating women
  • patients unable to understand the treatment protocol and sign informed consent and/or patients younger than 18 years old,
  • medical conditions that prevents an oral examination,
  • incapability to perform oral hygiene measures due to physical or mental disorders,
  • patients with uncontrolled systemic diseases or neoplasms, infection with HIV or hepatitis, cardiovascular disease, blood disorders (e.g. coagulation disorders) and severe osteoporosis,
  • patients who have received systemic antibiotics, corticosteroids, or immunosuppressive therapy within 3 months before periodontal evaluation (baseline), as well as those who chronically use nonsteroidal anti-inflammatory drugs, require antibiotic coverage for dental procedures, and those who are undergoing chronic treatment with medications known to affect periodontal health (such as phenytoin or cyclosporine),
  • alcohol or drug addiction
  • implants with mobility and/or occlusal overload.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Coimbra

Coimbra, Portugal

RECRUITING

Related Publications (7)

  • Derks J, Schaller D, Hakansson J, Wennstrom JL, Tomasi C, Berglundh T. Effectiveness of Implant Therapy Analyzed in a Swedish Population: Prevalence of Peri-implantitis. J Dent Res. 2016 Jan;95(1):43-9. doi: 10.1177/0022034515608832.

    PMID: 26701919BACKGROUND
  • Renvert S, Persson GR, Pirih FQ, Camargo PM. Peri-implant health, peri-implant mucositis, and peri-implantitis: Case definitions and diagnostic considerations. J Clin Periodontol. 2018 Jun;45 Suppl 20:S278-S285. doi: 10.1111/jcpe.12956.

    PMID: 29926496BACKGROUND
  • Berglundh T, Armitage G, Araujo MG, Avila-Ortiz G, Blanco J, Camargo PM, Chen S, Cochran D, Derks J, Figuero E, Hammerle CHF, Heitz-Mayfield LJA, Huynh-Ba G, Iacono V, Koo KT, Lambert F, McCauley L, Quirynen M, Renvert S, Salvi GE, Schwarz F, Tarnow D, Tomasi C, Wang HL, Zitzmann N. Peri-implant diseases and conditions: Consensus report of workgroup 4 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. J Clin Periodontol. 2018 Jun;45 Suppl 20:S286-S291. doi: 10.1111/jcpe.12957.

    PMID: 29926491BACKGROUND
  • Lee CT, Huang YW, Zhu L, Weltman R. Prevalences of peri-implantitis and peri-implant mucositis: systematic review and meta-analysis. J Dent. 2017 Jul;62:1-12. doi: 10.1016/j.jdent.2017.04.011. Epub 2017 May 3.

    PMID: 28478213BACKGROUND
  • Herrera D, Berglundh T, Schwarz F, Chapple I, Jepsen S, Sculean A, Kebschull M, Papapanou PN, Tonetti MS, Sanz M; EFP workshop participants and methodological consultant. Prevention and treatment of peri-implant diseases-The EFP S3 level clinical practice guideline. J Clin Periodontol. 2023 Jun;50 Suppl 26:4-76. doi: 10.1111/jcpe.13823. Epub 2023 Jun 4.

    PMID: 37271498BACKGROUND
  • Romandini M, Lima C, Pedrinaci I, Araoz A, Soldini MC, Sanz M. Prevalence and risk/protective indicators of peri-implant diseases: A university-representative cross-sectional study. Clin Oral Implants Res. 2021 Jan;32(1):112-122. doi: 10.1111/clr.13684. Epub 2020 Dec 29.

    PMID: 33210772BACKGROUND
  • Verket A, Koldsland OC, Bunaes D, Lie SA, Romandini M. Non-surgical therapy of peri-implant mucositis-Mechanical/physical approaches: A systematic review. J Clin Periodontol. 2023 Jun;50 Suppl 26:135-145. doi: 10.1111/jcpe.13789. Epub 2023 Feb 28.

    PMID: 36802083BACKGROUND

MeSH Terms

Interventions

Erythritol

Intervention Hierarchy (Ancestors)

Sugar AlcoholsAlcoholsOrganic ChemicalsCarbohydrates

Study Officials

  • Orlando Martins

    Visiting Assistant Professor

    STUDY DIRECTOR

Central Study Contacts

Orlando Martins

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Visiting Assistant Professor

Study Record Dates

First Submitted

May 18, 2024

First Posted

June 12, 2024

Study Start

March 18, 2024

Primary Completion

December 1, 2025

Study Completion

December 1, 2025

Last Updated

June 12, 2024

Record last verified: 2024-06

Locations